{
    "ticker": "COGT",
    "name": "Cogent Biosciences, Inc.",
    "description": "Cogent Biosciences, Inc. is a biotechnology company focused on developing innovative therapies for patients with genetically defined diseases, particularly those involving severe genetic mutations. Founded in 2015, Cogent is committed to advancing the understanding of disease mechanisms through its proprietary drug discovery platform and biomarker-driven clinical development. The company's lead product candidate, COGT-003, is aimed at treating patients with rare genetic disorders, and it has shown promising results in early clinical trials. Cogent's approach integrates cutting-edge genomics and biophysics to identify and validate drug targets, and it leverages a deep understanding of genetic science to optimize its therapeutic candidates. In addition to its main pipeline, Cogent is actively exploring partnerships with academic and industry leaders to expand its research capabilities and expedite the development of new treatments. With a dedicated team of scientists and industry veterans, Cogent is positioned to significantly impact the field of precision medicine and improve the lives of patients suffering from debilitating genetic conditions.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Cambridge, Massachusetts, USA",
    "founded": "2015",
    "website": "https://www.cogentbio.com",
    "ceo": "Andrew D. Allen",
    "social_media": {
        "twitter": "https://twitter.com/CogentBio",
        "linkedin": "https://www.linkedin.com/company/cogent-biosciences/"
    },
    "investor_relations": "https://ir.cogentbio.com",
    "key_executives": [
        {
            "name": "Andrew D. Allen",
            "position": "CEO"
        },
        {
            "name": "Rachel H. K. R. Sutherland",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "COGT-003"
            ]
        }
    ],
    "seo": {
        "meta_title": "Cogent Biosciences, Inc. | Innovating Genetic Disease Treatments",
        "meta_description": "Explore Cogent Biosciences, Inc., a leader in biotechnology focused on developing therapies for genetically defined diseases. Learn about their innovative approach and key products.",
        "keywords": [
            "Cogent Biosciences",
            "Biotechnology",
            "Genetic Diseases",
            "Precision Medicine",
            "COGT-003"
        ]
    },
    "faq": [
        {
            "question": "What does Cogent Biosciences do?",
            "answer": "Cogent Biosciences develops innovative therapies for patients with genetically defined diseases."
        },
        {
            "question": "Who is the CEO of Cogent Biosciences?",
            "answer": "Andrew D. Allen is the CEO of Cogent Biosciences, Inc."
        },
        {
            "question": "Where is Cogent Biosciences headquartered?",
            "answer": "Cogent Biosciences is headquartered in Cambridge, Massachusetts, USA."
        },
        {
            "question": "What is Cogent's lead product candidate?",
            "answer": "Cogent's lead product candidate is COGT-003, aimed at treating rare genetic disorders."
        },
        {
            "question": "When was Cogent Biosciences founded?",
            "answer": "Cogent Biosciences was founded in 2015."
        }
    ],
    "competitors": [
        "CRSP",
        "SGEN",
        "EDIT",
        "ALNY"
    ],
    "related_stocks": [
        "AMGN",
        "VRTX",
        "REGN",
        "GILD"
    ]
}